French Sanofi SAs second Phase III trial of duplimab demonstrated a 34% reduction in exacerbations and significant lung function improvements.
Tag Archive for: COPD
C4X Discovery Holdings plc has exclusively licenced its NRF2 Activator programme to AstraZeneca and has got an upfront payment of $2m.
EpiEndo Pharmaceuticals ehf got the green light for a Phase IIa COPD trial with its non-anbibiotic macrolide EP395